Low levels of cortisol synthesis lead to an overproduction of ACTH; this continuously stimulates the adrenal gland (in order to produce more cortisol), giving rise to hyperplasia of the adrenal tissue (Refs 1, 2).
The three main categories of steroid honnones (mineralocorticoids, glucocorticoids and adrenal androgens) are synthesised in the adrenal cortex from cholesterol. The enzymes (and corresponding genes) necessary for the successive steps of steroid honnone biosynthesis are depicted in Figure 1 . The different clinical phenotypes of CAH are best understood by a comprehensive analysis of the enzymatic deficiency and thẽ Cortisol, the principal glucocorticoid, is produced by the adrenal zona fasciculata. Cortisol has multiple and important functions in most of the metabolic pathways: it plays a key role in blood sugar maintenance, promoting gluconeogenesis during periods of physical or psychological stress, regulates blood pressure and homeostasis, and supports cardiovascular and immunological functions. In addition, it was recently demonstrated for the first time that during early fetal life, between 8 and 10 weeks post-conception, cortisol synthesised by human adrenal cortex is able to down-regulate androgen 9 Figure 1 . Principal pathways 01steroid hormone biosynthesis from cholesterol. (Legend; soo previous page for figure.) Major products of adrenal steroidogenesis are indicated with a blue box. Enzymatic activities catalysing each bioconversion (coloured arrows) are shown in the key below, where genes encoding each enzyme are given in italics (CYP gene symbols show that the corresponding enzyme is a member of the cytochrome P450 superfamily). The steroidogenic acute regulatory protein (STAR)promotes cholesterol transport to the inner mitochondrial membrane (not shown) (Ref. 140). The first step of steroidogenesis is the conversion of cholesterol to pregnenolone; this requires three reactions (20a-hydroxylation, 22hydroxylation, and cleavage of cholesterol side chain), which are ali catalysed by cholesterol 20-22desmolase (Ref. 88). (a) Mineralocorticoid synthesis. The biosynthesis of mineralocorticoids (in the zona glomerulosa), requires the action of 3f3-hydroxysteroid dehydrogenase, which converts pregnenolone to progesterone. This is subsequently converted to deoxycorticosterone by 21-hydroxylase. The last enzymatic steps that culminate in aldosterone biosynthesis are performed by a single enzymealdosterone synthase (encoded by CYP11 82 gene)which has three enzymatic activities: 11 f3-hydroxylation of deoxycorticosterone, 18-hydroxylation and 18-oxidation of corticosterone. (b) Glucocorticoid synthesis. To produce the glucocorticoid cortisol (in the zona fasciculata), the CYP17A1-encoded enzyme catalyses the bioconversion of pregnenolone to 17-hydroxypregnenolone. 3f3-hydroxysteroid dehydrogenase uses 17-hydroxypregnenolone as a substrate, converting it to 17-hydroxyprogesterone, which is ais o produced by the 17a-hydroxylation of progesterone. 21-hydroxylase mediates the bioconversion of 17-hydroxyprogesterone to 11-deoxycortisol, which is converted into cortisol by the action of 11f3-hydroxylase. (c) Sex steroid hormone synthesis. The production of adrenal androgens results from the conversion of 17-hydroxypregnenolone to dehydroepiandrosterone by the CYP17A1 enzyme as a result of its 17,20-lyase activity, and dehydroepiandrosterone is subsequently converted by 3f3-hydroxysteroid dehydrogenase to androstenedione. The latter is also converted by the CYP17A1 enzyme from 17-hydroxyprogesterone(Ref. 7) . There are several isozymes with 17f3-hydroxysteroiddehydrogenase activity.Whiletype 5 isozymeHSD1785(encoded by AKR1C3)converts androstenedioneintotestosterone in the adrenal gland during early fetal life (Ref. 5), other isozymes, like HSD1783 and HSD1781, are responsible for testosterone biosynthesisin the testes and ovaries. During puberty, aromataseconverts androstenedioneand testosteroneto oestrone and oestradiol,respectively.Testosteroneis metabolisedto dihydrotestosteroneby 5a-reductase,predominantlyin genitalskin and in other androgentarget tissues. The enzymatic deficiencies thatmost frequently cause CAH are defects in 21-hydroxylase, 1113hydroxylase, 313-hydroxysteroid dehydrogenase, and less frequently 17a.-hydroxylasej17,20lyase, cholesterol 20-22-desmolase and the transporter protein StAR (steroidogenic acute regulatory protein). In addition, a new form of CAH was recently described, characterised by deficiencies in both 21-hydroxylase and 17a.-hydroxylasej17,20-lyase activities as a result of mutations in the electron donor enzyme P450 oxidoreductase (POR) (Refs 9, 10). Most patients with POR deficiency have skeletal malformations, genital anomalies in both sexes and abnormal steroid profiles (Refs 10, 11, 12). The clinical and molecular features of alI these enzymatic defects are summarised in Table 1 . For deficiency in 21-hydroxylase, the main subject of this paper, a more detailed review is presented in the next sections.
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Clinical features of 21-hydroxylase deficiency 21-hydroxylase deficiency (21-0HD) is the most common cause of CAH, accounting for 90-95% of alI cases. Patients with 21-OHD have a deficiency in cortisol biosynthesis, which in most of the severe cases is also accompanied by aldosterone deficiency. The decreased adrenal secretion of cortisol gives rise, because of the absence of negative feedback to the hypothalamus and pituitary, to an increased secretion of CRH and ACTH. The steroid precursors prior to this enzymatic deficiency (progesterone and 17-hydroxyprogesterone) are accumulated and shunted through the adrenal androgen biosynthetic pathway. The increased secretion of adrenal androgens from the eighth week of gestation, and the resulting production of high levels of testosterone and dihydrotestosterone, particularly affects sexual dilierentiation in females, and causes advanced somatic development in both sexes during childhood (Ref. 13). Clinically, although there is a continuous spectrum of phenotypic manifestations associated with this disease, it has been useful to divide 21-0HD into three forms: salt-wasting classical 21-0HD, simple virilising classical 21-0HD, and nonclassical21-OHD. ...c :7
OT"" 0C\1 ::J (.) O 'I-renal salt-wasting account for three-quarters of classical 21-0HD cases. In addition to having a severe cortisol deficiency, they do not synthesise enough aldosterone and therefore are not able to maintain sodium homeostasis. Severely affected patients usualIy present between the first and fourth weeks of age with hyponatraemia, hyperkalaemia, hyperreninaemia, hypovolaemic shock and hypoglycaemia. Other symptoms are also common, such as lethargy, poor feeding, vomiting and failure to thrive. In the female fetus, androgen excess causes variable degrees of external genitalia virilisation, and consequently newborn females have genital ambiguity or male-resembling external genitalia with bilateral cryptorchidism, which may result in errors of sex assignment at birth. In the male fetus, the testicular androgens normally produced at high levels induce the normal masculinisation of the external genitalia, and the excess of adrenal androgens usually has no effect until childhood, although sometimes a macrogenitossomia at birth is observed. 
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Molecular features of 21-0HD
The CYP21A2 locus Human adrenal 21-hydroxylase is encoded by the CYP21A2 gene, also previously called CYP21 and CYP21B, which is located on 6p21.3 within class m HLA,~30 kb from a pseudogene (CYP21A1P; known also as CYP21P and CYP21A). These two genes share about 98% homology in their ten exons and about 96% in the introns, but CYP21A1P is inactive because of the presence of several deleterious mutations (Refs 21, 22) . The gene and the pseudogene are included in what is called the RCCX region (Fig. 2) , which, in the most common alleles, has a bimodular form (RCCX-RCCX), composed of two sets of four genes arranged in tandem: The direct screening of CYP21A2 mutations C requires two steps. The first one is the isolation O of the CYP21A2 gene from the pseudogene, O since the latter is inactive and has most of the mutations of interest. Currently, this step is usually performed by PCR with primers specific for CYP21A2, which do not allow the concomitant amplification of CYP21AIP (Refs 40, 41) . The product of this first step is used as template DNA for detection of mutations in the second step. The screening of the most common mutations is regularly 
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virilising classical 21-0HD, and three to saltwasting classica121-OHD. The mutation g.655A/ C> G has been reported both in salt-wasting and in simple virilising cases. This mutation activates cryptic splicing receptor sequences causing the incorrect processing of almost all the mRNA. A small amount of normally spliced rnRNA can be detected in cell cultures; therefore, in the absence of other mutations, small quantities of functional enzyme can be produced, thus preventing the salt-wasting crisis (Refs 37, 38).
Molecular diagnosis of 21-0HD
As discussed above, 21-OHD is diagnosed biochemically by measuring levels of 17-hydroxyprogesterone after stimulation with ACTH, but this method does not differentiate 12 or promoter region of the CYP21A2 gene, it is ió important to evaluate and predict its 'ã. 8 Genotype-phenotype correlations CYP21A2 mutations can be predicted to cause a certain phenotype -salt-wasting, simple virilising or nonclassical -on the basis of the reduction of the enzymatic activity they produce.
However, most CAH patients are actually compound heterozygous for two or more mutations. Since 21-0HD is an autosomal recessive disease, the phenotype of the patient should reflect the mutation that is predicted to cause a less severe impairment of the enzymatic activity. This approach to predicting phenotype has been shown to be correct in 80% to~100% of cases for null mutations and patients with salt-wasting 21-0HD, and for the p.V281L mutation and patients with nonclassical 21-OHD (Refs 13, 29, 62). Slight deviations to this correlation occur in the forms of the disease with intermediate severity and with mutations such as p.I172N, g.655AjC > G or p.P30L, which in vivo may produce variable 21hydroxylase activity. Sometimes it is difficult to differentiate between the simple virilising and nonclassical forms in male patients, because their symptoms of androgen excess are usually not detected at birth, so they may be incorrectly assigned as nonclassical 21-0HD patients. Otherwise, some of the causes that contribute to discrepancies between the predicted and the patient's phenotype may be the association of mutations of different severities in the same or in distinct alleles, the existence of mutations that impair CYP21A2 gene expression, and the presence of alterations in other genes, which may disturb 21-hydroxylase function or expert reviews in molecular medicine '1->..
expression. It has also been proposed that some O (,) alterations usually considered to be.~c: polymorphisms, such as p. K102R 
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elucidating the physiological functions of these (1) with the use of functional studies and animal P. genes or gene products direct1y associated with (1) CAH and involved in the same or in C) multiple physiological pathways. The integration :: of these data obtained from a large number of a patients with pharmacogenomic studies and r'}! eventually with gene therapy will have a great impact in individual and global health care (Refs 74, 75).
At present, there is consideiable expectation that gene therapy and autograft transplantation of genetically modified adrenal cortical stem cells or multipotent mesenchymal bone marrow cells may achieve a definitive cure for patients with CAH or with other endocrine pathologies 
